Clinical Outcomes After Proton Therapy Reirradiation for Recurrent Malignant Glioma: Analysis From the Prospective Proton Collaborative Group Registry
In the largest series of glioma PT-ReRT reported to date, retreatment was well tolerated with variable outcomes based on clinical prognostic factors. Toxicity rates were similar compared to photon-based literature despite a high median ReRT prescription dose.
Authors
- Robert H. Press (ORCID: https://orcid.org/0000-0002-3297-3945)
- Rupesh Kotecha (ORCID: https://orcid.org/0000-0001-6927-0402)
- J. Chang (ORCID: https://orcid.org/0000-0002-2059-6599)
- Stephen A. Mihalcik (ORCID: https://orcid.org/0000-0003-2145-467X)
- C. Jake Wang
- Omer Gal (ORCID: https://orcid.org/0000-0002-5140-9362)
- Charles B. Simone (ORCID: https://orcid.org/0000-0002-0867-3694)
- Lia M. Halasz (ORCID: https://orcid.org/0000-0001-9581-4901)
- Carlos Vargas (ORCID: https://orcid.org/0000-0002-1614-3562)
- J. Isabelle Choi (ORCID: https://orcid.org/0009-0004-1273-5749)
- Henry Tsai
Institutions
- University of Washington (US)
- University of Oklahoma Medical Center (US)
- Willis-Knighton Cancer Center (US)
- New York Proton Center (US)
- Miami Heart Research Institute (US)
- Mayo Clinic in Florida (US)
- Northwestern Medicine (US)
- ProCure (United States) (US)
Publication Details
- Journal
- Advances in Radiation Oncology
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1016/j.adro.2025.101834
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00